Fri, Jul 25, 2014 - Page 13 News List

Medigen is set to release results of its liver drug trials

By Camaron Kao  /  Staff reporter

Drug and vaccine manufacturer Medigen Biotechnology Corp (基亞) said yesterday that it is to release the interim results of phase three clinical trials for its new drug to treat liver cancer on Sunday evening.

Hospitals conducting clinical trials for Medigen are to hand over the data of the trials to Protech Pharmaservices Corp (佳生) on Friday after the stock market closes, and Protech Pharmaservices in turn are to give the data to independent statisticians for analysis, Medigen chairman Stanley Chang (張世宗) said.

Chang said he is cautiously optimistic about the results, which are to decide if the company can file for a new drug permit or complete the entire trial process first or even drop the testing entirely.

Medigen started the phase three trials for the drug in 2012 in 25 medical centers across South Korea, Taiwan, China and Hong Kong, Chang said.

The company recruited 520 patients, and about 140 patients had cancer recurrence, he added.

Citing statistics compiled by Morgan Stanley, Chang said the market for drugs to treat liver cancer in China is about NT$5 billion (US$166.79 million) to NT$22.5 billion a year.

The global market for these drugs is NT$62 billion a year, while the market for Chinese patients worldwide is about NT$16.8 billion a year, Chang said, citing Industrial Technology Research Institute.

Meanwhile, Medigen is also in talks with Novartis International AG for possible cooperation on a monoclonal antibody for treating avian influenza, which it developed last quarter.

Winston Medical Supply Co (溫士頓), which Medigen owns a 68 percent share of, is also in talks with two Japanese companies and one Chinese company on selling products for treating eye diseases in China, Chang said.

Gross margin for Winston is set to increase to around 20 percent this year from 10 percent last year, it said.

From January through last month, Medigen reported revenue of NT$177.88 million, up 3.4 times from a year ago.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top